|
1
|
Kamposioras K and Papadopoulos V:
Pancreatic adenocarcinoma treatment. Anticipating better results.
European Society for Medical Oncology, Lugano. 2012, https://www.esmo.org/Career-Development/Young-Oncologists-Corner/Journal-Club/Pancreatic-Adenocarcinoma-Treatment.-Anticipating-Better-ResultsNovember
27–2012
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bakkevold KE, Arnesjø B, Dahl O and
Kambestad B: Adjuvant combination chemotherapy (AMF) following
radical resection of carcinoma of the pancreas and papilla of
Vater-results of a controlled, prospective, randomised multicentre
study. Eur J Cancer. 29:698–703. 1993. View Article : Google Scholar
|
|
6
|
Kuhlmann KF, de Castro SM, Wesseling JG,
ten Kate FJ, Offerhaus GJ, Busch OR, van Gulik TM, Obertop H and
Gouma DJ: Surgical treatment of pancreatic adenocarcinoma: Actual
survival and prognostic factors in 343 patients. Eur J Cancer.
40:549–558. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsao JI, Rossi RL and Lowell JA:
Pylorus-preserving pancreatoduodenectomy. Is it an adequate cancer
operation. Arch Surg. 129:405. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann
JV, Hruban RH, Goodman SN, Dooley WC, Coleman J and Pitt HA:
Pancreaticoduodenectomy for cancer of the head of the pancreas. 201
patients. Ann Surg. 221:721–731. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD,
Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, et
al: Six hundred fifty consecutive pancreaticoduodenectomies in the
1990s: Pathology, complications, and outcomes. Ann Surg.
226:248–257. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Millikan KW, Deziel DJ, Silverstein JC,
Kanjo TM, Christein JD, Doolas A and Prinz RA: Prognostic factors
associated with resectable adenocarcinoma of the head of the
pancreas. Am Surg. 65:618–623. 1999.PubMed/NCBI
|
|
11
|
Benassai G, Mastrorilli M, Quarto G,
Cappiello A, Giani U and Mosella G: Survival after
pancreaticoduodenectomy for ductal adenocarcinoma of the head of
the pancreas. Chir Ital. 52:263–270. 2000.PubMed/NCBI
|
|
12
|
Dalton RR, Sarr MG, van Heerden JA and
Colby TV: Carcinoma of the body and tail of the pancreas: Is
curative resection justified. Surgery. 111:489–494. 1992.PubMed/NCBI
|
|
13
|
Johnson CD, Schwall G, Flechtenmacher J
and Trede M: Resection for adenocarcinoma of the body and tail of
the pancreas. Br J Surg. 80:1177–1179. 2010. View Article : Google Scholar
|
|
14
|
Khorana AA, Mangu PB and Katz MHG:
Potentially curable pancreatic cancer: American society of clinical
oncology clinical practice guideline. J Oncol Prac. 13:388–391.
2017. View Article : Google Scholar
|
|
15
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suárez Y and Sessa WC: microRNAs as novel
regulators of angiogenesis. Circ Res. 104:442–454. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu P, Guo M and Hay BA: MicroRNAs and the
regulation of cell death. Trends Genet. 20:617–624. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartel DP and Chen CZ: Micromanagers of
gene expression: The potentially widespread influence of metazoan
microRNAs. Nature Rev Genet. 5:396–400. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mcguire A, Brown JAL and Kerin MJ:
Metastatic breast cancer: The potential of miRNA for diagnosis and
treatment monitoring. Cancer Metastasis Rev. 34:145–155. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maura F, Cutrona G, Mosca L, Matis S,
Lionetti M, Fabris S, Agnelli L, Colombo M, Massucco C, Ferracin M,
et al: Association between gene and miRNA expression profiles and
stereotyped subset #4 B-cell receptor in chronic lymphocytic
leukemia. Leuk Lymphoma. 56:3150–3158. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song Q, Xu Y, Yang C, Chen Z, Jia C, Chen
J, Zhang Y, Lai P, Fan X, Zhou X, et al: miR-483-5p promotes
invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1
and ALCAM. Cancer Res. 74:3031–3042. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Singh S, Chitkara D, Kumar V, Behrman SW
and Mahato RI: miRNA profiling in pancreatic cancer and restoration
of chemosensitivity. Cancer Lett. 334:211–220. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wald P, Liu XS, Pettit C, Dillhoff M,
Manilchuk A, Schmidt C, Wuthrick E, Chen W and Williams TM:
Prognostic value of microRNA expression levels in pancreatic
adenocarcinoma: A review of the literature. Oncotarget.
8:73345–73361. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang P, Zhu CF, Ma MZ, Chen G, Song M,
Zeng ZL, Lu WH, Yang J, Wen S, Chiao PJ, et al: Micro-RNA-155 is
induced by K-Ras oncogenic signal and promotes ROS stress in
pancreatic cancer. Oncotarget. 6:21148–21158. 2015.PubMed/NCBI
|
|
25
|
Gironella M, Seux M, Xie MJ, Cano C,
Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, et
al: Tumor protein 53-induced nuclear protein 1 expression is
repressed by miR-155, and its restoration inhibits pancreatic tumor
development. Proc Natl Acad Sci USA. 104:16170–16175. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang XJ, Ye H, Zeng CW, He B, Zhang H and
Chen YQ: Dysregulation of miR-15a and miR-214 in human pancreatic
cancer. J Hematol Oncol. 3:462010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Giulietti M, Occhipinti G, Principato G
and Piva F: Identification of candidate miRNA biomarkers for
pancreatic ductal adenocarcinoma by weighted gene co-expression
network analysis. Cell Oncol (Dordr). 40:1–12. 2017.PubMed/NCBI
|
|
28
|
Dhayat SA, Abdeen B, Köhler G, Senninger
N, Haier J and Mardin WA: MicroRNA-100 and microRNA-21 as markers
of survival and chemotherapy response in pancreatic ductal
adenocarcinoma UICC stage II. Clin Epigenetics. 7:1322015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hwang JH, Voortman J, Giovannetti E,
Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH,
et al: Identification of MicroRNA-21 as a biomarker for
chemoresistance and clinical outcome following adjuvant therapy in
resectable pancreatic cancer. PLoS One. 5:e106302010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang C, Yu XJ, Guo XZ, Sun MH, Wang Z,
Song Y, Ni QX, Li HY, Mukaida N and Li YY: MicroRNA-33a-mediated
downregulation of Pim-3 kinase expression renders human pancreatic
cancer cells sensitivity to gemcitabine. Oncotarget. 6:14440–14455.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Khan K, Cunningham D, Peckitt C, Barton S,
Tait D, Hawkins M, Watkins D, Starling N, Rao S, Begum R, et al:
miR-21 expression and clinical outcome in locally advanced
pancreatic cancer: Exploratory analysis of the pancreatic cancer
Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget.
7:12672–12681. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li J, Wu H, Li W, Yin L, Guo S, Xu X,
Ouyang Y, Zhao Z, Liu S, Tian Y, et al: Downregulated miR-506
expression facilitates pancreatic cancer progression and
chemoresistance via SPHK1/Akt/NF-κB signaling. Oncogene.
35:5501–5514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang B and Horvath S: A general framework
for weighted gene co-expression network analysis. Stat Appl Genet
Mol Biol. 4:Article 17. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cuccurullo V: AJCC cancer staging
handbook: From the AJCC cancer staging manual (7th edition).
European J Nuclear Med Mol Imag. 38:4082011. View Article : Google Scholar
|
|
35
|
Langfelder P and Horvath S: WGCNA: An R
package for weighted correlation network analysis. BMC
Bioinformatics. 9:5592008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Barrett T, Troup DB, Wilhite SE, Ledoux P,
Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M,
Marshall KA, et al: NCBI GEO: Archive for high-throughput
functional genomic data. Nucleic Acids Res. 37:D885–D890. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yip AM and Horvath S: Gene network
interconnectedness and the generalized topological overlap measure.
BMC Bioinformatics. 8:222007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Williams S: Pearson's correlation
coefficient. N Z Med J. 109:381996.PubMed/NCBI
|
|
39
|
Shi K, Bing ZT, Cao GQ, Guo L, Cao YN,
Jiang HO and Zhang MX: Identify the signature genes for diagnose of
uveal melanoma by weight gene co-expression network analysis. Int J
Ophthalmol. 8:269–274. 2015.PubMed/NCBI
|
|
40
|
Jeong H, Mason SP, Barabási AL and Oltvai
ZN: Lethality and centrality in protein networks. Nature.
411:41–42. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liang H and Li WH: Gene essentiality, gene
duplicability and protein connectivity in human and mouse. Trends
Genet. 23:375–378. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk-database: Prediction of possible miRNA binding sites by
‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wong N and Wang X: miRDB: An online
resource for microRNA target prediction and functional annotations.
Nucleic Acids Res. 43:D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
ELife. 4:2015. View Article : Google Scholar
|
|
46
|
Doron B, Manda W, Aaron G, Marks DS and
Chris S: The microRNA.org resource: Targets and expression. Nucleic
Acids Res. 36:149–153. 2008.
|
|
47
|
Chou CH, Shrestha S, Yang CD, Chang NW,
Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, et al: miRTarBase
update 2018: A resource for experimentally validated
microRNA-target interactions. Nucleic Acids Res. 46:D296–D302.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M
and Rajewsky N: Combinatorial microRNA target predictions. Nat
Genet. 37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jiao X, Sherman BT, Huang DW, Stephens R,
Baseler MW, Lane HC and Lempicki RA: DAVID-WS: A stateful web
service to facilitate gene/protein list analysis. Bioinformatics.
28:1805–1806. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Freije WA, Castrovargas FE, Fang Z,
Horvath S, Cloughesy T, Liau LM, Mischel PS and Nelson SF: Gene
expression profiling of gliomas strongly predicts survival. Cancer
Res. 64:6503–6510. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cho HJ, Yu A, Kim S, Kang J and Hong S-M:
Robust likelihood-based survival modeling with microarray sata. J
Stat Softw. 29:1–16. 2009. View Article : Google Scholar
|
|
52
|
Kolde R: Pheatmap: Pretty Heatmaps.
Version 1.0.10. https://cran.r-project.org/web/packages/pheatmap/index.htmlMay
19–2018
|
|
53
|
Bukki J: Pancreatic adenocarcinoma. N Engl
J Med. 371:2139–2140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Guo S, Fesler A, Wang H and Ju J: microRNA
based prognostic biomarkers in pancreatic Cancer. Biomark Res.
6:182018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yu IS and Cheung WY: A Contemporary review
of the treatment landscape and the role of predictive and
prognostic biomarkers in pancreatic adenocarcinoma. Can J
Gastroenterol Hepatol. 2018:18635352018.PubMed/NCBI
|
|
56
|
Li J, Li YX and Li YY: Differential
rebgulatory analysis based on coexpression network in cancer
research. Biomed Res Int. 2016:42412932016.PubMed/NCBI
|
|
57
|
Chiang KC, Yeh CN, Ueng SH, Hsu JT, Yeh
TS, Jan YY, Hwang TL and Chen MF: Clinicodemographic aspect of
resectable pancreatic cancer and prognostic factors for resectable
cancer. World J Surg Oncol. 10:772012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yamamoto T, Yagi S, Kinoshita H, Sakamoto
Y, Okada K, Uryuhara K, Morimoto T, Kaihara S and Hosotani R:
Long-term survival after resection of pancreatic cancer: A
single-center retrospective analysis. World J Gastroenterol.
21:262–268. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hanahan D and Robert RA: Weinberg:
Hallmarks of cancer: The next generation. Cell. 144:644–674. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ho A and Dowdy SF: Regulation of G(1)
cell-cycle progression by oncogenes and tumor suppressor genes.
Curr Opin Genet Dev. 12:47–52. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Holmes K, Roberts OL, Thomas AM and Cross
MJ: Vascular endothelial growth factor receptor-2: Structure,
function, intracellular signalling and therapeutic inhibition. Cell
Signal. 19:2003–2012. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Massagué J, Blain SW and Lo RS: TGFbeta
signaling in growth control, cancer, and heritable disorders. Cell.
103:295–309. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhang H, Liu C, Kong Y, Huang H, Wang C
and Zhang H: TGFβ signaling in pancreatic ductal adenocarcinoma.
Tumor Biol. 36:1613–1618. 2015. View Article : Google Scholar
|
|
64
|
Katz LH, Likhter M, Jogunoori W, Belkin M,
Ohshiro K and Mishra L: TGF-β signaling in liver and
gastrointestinal cancers. Cancer Lett. 379:166–172. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Jonckheere N, Vasseur R and Van SI: The
cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell
signaling network, target genes, biological processes to
therapeutic targeting. Crit Rev Oncol Hematol. 111:7–19. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Mikhail V: Blagosklonny: Cell immortality
and hallmarks of cancer. Cell Cycle. 2:296–299. 2003.PubMed/NCBI
|
|
67
|
Farhan M, Wang H, Gaur U, Little PJ, Xu J
and Zheng W: FOXO signaling pathways as therapeutic targets in
cancer. Int J Biol Sci. 13:815–827. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Moore MJ: From birth to death: The complex
lives of eukaryotic mRNAs. Science. 309:1514–1518. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Dan I, Watanabe NM and Kusumi A: The Ste20
group kinases as regulators of MAP kinase cascades. Trends Cell
Biol. 11:220–230. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Dogan F and Biray AC: Correlation between
telomerase and mTOR pathway in cancer stem cells. Gene.
641:235–239. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Frampton AE, Krell J, Jamieson NB, Gall
TMH, Giovannetti E, Funel N, Mato Prado M, Krell D, Habib NA,
Castellano L, et al: microRNAs with prognostic significance in
pancreatic ductal adenocarcinoma: A meta-analysis. Eur J Cancer.
51:1389–1404. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhou X, Wang X, Huang Z, Xu L, Zhu W and
Liu P: An ER-associated miRNA signature predicts prognosis in
ER-positive breast cancer. J Exp Clin Cancer Res. 33:942014.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Li X, Zhang Y, Zhang Y, Ding J, Wu K and
Fan D: Survival prediction of gastric cancer by a seven-microRNA
signature. Gut. 59:579–585. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhou X, Huang Z, Xu L, Zhu M, Zhang L,
Zhang H, Wang X, Li H, Zhu W, Shu Y and Liu P: A panel of 13-miRNA
signature as a potential biomarker for predicting survival in
pancreatic cancer. Oncotarget. 7:69616–69624. 2016.PubMed/NCBI
|
|
75
|
Greither T, Grochola LF, Udelnow A,
Lautenschläger C, Würl P and Taubert H: Elevated expression of
microRNAs 155: 203, 210 and 222 in pancreatic tumors is associated
with poorer survival. Int J Cancer. 126:73–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Guan B, Wu K, Zeng J, Xu S, Mu L, Yang G,
Wang K, Ma Z, Tian J, Shi Q, et al: Tumor-suppressive microRNA-218
inhibits tumor angiogenesis via targeting the mTOR component RICTOR
in prostate cancer. Oncotarget. 8:8162–8172. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhu K, Ding H, Wang W, Liao Z, Fu Z, Hong
Y, Zhou Y, Zhang CY and Chen X: Tumor-suppressive miR-218-5p
inhibits cancer cell proliferation and migration via EGFR in
non-small cell lung cancer. Oncotarget. 7:28075–28085.
2016.PubMed/NCBI
|
|
78
|
Feng Z, Zhang L, Zhou J, Zhou S, Li L, Guo
X, Feng G, Ma Z, Huang W and Huang F: mir-218-2 promotes
glioblastomas growth, invasion and drug resistance by targeting
CDC27. Oncotarget. 8:6304–6318. 2017.PubMed/NCBI
|
|
79
|
Guan H, Wei G, Wu J, Fang D, Liao Z, Xiao
H, Li M and Li Y: Down-regulation of miR-218-2 and its host gene
SLIT3 cooperate to promote invasion and progression of thyroid
cancer. J Clin Endocrinol Metab. 98:E1334–E1344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Xie H, Zhang Q, Zhou H, Zhou J, Zhang J,
Jiang Y, Wang J, Meng X, Zeng L and Jiang X: microRNA-889 is
downregulated by histone deacetylase inhibitors and confers
resistance to natural killer cytotoxicity in hepatocellular
carcinoma cells. Cytotechnology. 70:513–521. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Xu Y, He J, Wang Y, Zhu X, Pan Q, Xie Q
and Sun F: miR-889 promotes proliferation of esophageal squamous
cell carcinomas through DAB2IP. FEBS Lett. 589:1127–1135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Molina-Pinelo S, Carnero A, Rivera F,
Estevez-Garcia P, Bozada JM, Limon ML, Benavent M, Gomez J, Pastor
MD, Chaves M, et al: MiR-107 and miR-99a-3p predict chemotherapy
response in patients with advanced colorectal cancer. BMC Cancer.
14:6562014. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Chang RM, Xiao S, Lei X, Yang H, Fang F
and Yang LY: miRNA-487a promotes proliferation and metastasis in
hepatocellular carcinoma. Clin Cancer Res. 23:2593–2604. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Gonzalez-Vallinas M, Rodriguez-Paredes M,
Albrecht M, Sticht C, Stichel D, Gutekunst J, Pitea A, Sass S,
Sánchez-Rivera FJ, Bermejo JL, et al: Epigenetically regulated
chromosome 14q32 miRNA cluster induces metastasis and predicts poor
prognosis in lung adenocarcinoma patients. Mol Cancer Res.
16:390–402. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ma M, He M, Jiang Q, Yan Y, Guan S, Zhang
J, Yu Z, Chen Q, Sun M, Yao W, et al: MiR-487a promotes
TGF-β1-induced EMT, the migration and invasion of breast cancer
cells by directly targeting MAGI2. Int J Biol Sci. 12:397–408.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Stylli SS, Adamides AA, Koldej RM, Luwor
RB, Ritchie DS, Ziogas J and Kaye AH: miRNA expression profiling of
cerebrospinal fluid in patients with aneurysmal subarachnoid
hemorrhage. J Neurosurg. 126:1131–1139. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Fisher AJ, Cipolla E, Varre A, Gu H,
Mickler EA and Vittal R: Potential mechanisms underlying
TGF-β-mediated complement activation in lung fibrosis. Cell Mol Med
Open Access. 3:142017. View Article : Google Scholar : PubMed/NCBI
|
